Understanding patients' care barriers in the treatment of venous thromboembolism
- PMID: 31102162
- DOI: 10.1007/s11239-019-01880-3
Understanding patients' care barriers in the treatment of venous thromboembolism
Abstract
Venous thromboembolism (VTE) is a major health care problem. There are common barriers to quality healthcare but are these barriers the same for VTE patients? A national online survey was administered to adults who had experienced a recent VTE event. The survey assessed perceptions of VTE care barriers: (1) Difficulty to meet healthcare costs related to VTE care; (2) difficulty to meet costs for VTE prescription medications; (3) difficulty with transportation to get VTE care; and (4) the degree of support of others needed to get VTE care. Each question was correlated with patient demographics including income level, place of residence, current work status, and health insurance; care related patient harms experienced with the VTE episode; number of lifetime VTE events; beliefs concerning VTE outcomes, and oral anticoagulant therapy type. Logistic regression analysis was used to determine the effect of independent variables on barriers to VTE care. Approximately 30% of VTE patients reported at least one significant barrier to VTE care. Patients rated healthcare costs and VTE prescription medication costs mildly difficult. The odds of reporting barriers were positively associated with the number of DVTs experienced in the previous 2 years. VTE-related depression was also moderately associated with increased odds of reporting significant VTE care barriers. Nearly 1 in 3 VTE sufferers reported significant barriers to VTE care, with healthcare costs and VTE medication costs being the most common. Efforts to identify patients who may experience barriers should be sought early in care.
Keywords: Anticoagulation; Care barriers; Deep vein thrombosis; Pulmonary embolism; Survey; Venous thromboembolism.
Similar articles
-
Prevalence and correlates of bleeding and emotional harms in a national US sample of patients with venous thromboembolism: A cross-sectional structural equation model.Thromb Res. 2018 Dec;172:181-187. doi: 10.1016/j.thromres.2018.05.025. Epub 2018 May 23. Thromb Res. 2018. PMID: 29843918
-
Patient Satisfaction With Venous Thromboembolism Treatment.Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619864663. doi: 10.1177/1076029619864663. Clin Appl Thromb Hemost. 2019. PMID: 31402687 Free PMC article.
-
Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?Clin Appl Thromb Hemost. 2017 Sep;23(6):532-541. doi: 10.1177/1076029616680475. Epub 2016 Nov 30. Clin Appl Thromb Hemost. 2017. PMID: 27899520
-
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.BMJ. 2019 Jul 24;366:l4363. doi: 10.1136/bmj.l4363. BMJ. 2019. PMID: 31340984 Free PMC article.
-
Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy.J Cardiol. 2015 Dec;66(6):451-9. doi: 10.1016/j.jjcc.2015.03.012. Epub 2015 Apr 18. J Cardiol. 2015. PMID: 25896176 Review.
Cited by
-
Health Literacy and Treatment Satisfaction Among Patients with Venous Thromboembolism.J Gen Intern Med. 2023 May;38(7):1585-1592. doi: 10.1007/s11606-022-07852-3. Epub 2022 Nov 3. J Gen Intern Med. 2023. PMID: 36326991 Free PMC article.
-
A descriptive study of antithrombotic medication patterns in adult patients with recent venous thromboembolism.Pharm Pract (Granada). 2019 Jul-Sep;17(3):1539. doi: 10.18549/PharmPract.2019.3.1539. Epub 2019 Aug 22. Pharm Pract (Granada). 2019. PMID: 31592294 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources